

学内グラント 終了後報告書

平成19年度 学内グラント報告書

HIF-1 α を分子標的とする卵巣癌治療へのアプローチ

研究代表者 安田 政実(埼玉医科大学 国際医療センター 病理診断科)

研究成果

論文(英文)

1. Kajiwar H, Kumaki N, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY. A case of oncocyctic carcinoma of the endometrium. Arch Gynecol Obstet 2009;279:733-9.
2. Kajiwar H, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix. Arch Gynecol Obstet 2009;279:521-5.
3. Hirabayashi K, Yasuda M, Kajiwar H, Itoh J, Miyazawa M, Hirasawa T, Muramatsu T, Murakami M, Mikami M, Osamura RY. Alterations in mucin expression in ovarian mucinous tumors: immunohistochemical analysis of MUC2, MUC5AC, MUC6, and CD10 expression. Acta Histochem Cytochem 2008;41:15-21.
4. Yasuda M, Miyazawa M, Fujita M, Kajiwar H, Iida T, Hirasawa T, Muramatsu T, Murakami M, Mikami M, Saitoh K, Shimizu M, Takekoshi S, Osamura RY. Expression of hypoxia inducible factor-1 α (HIF-1 α) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep 2008;19:111-6.
5. Iida T, Yasuda M, Miyazawa M, Fujita M, Osamura RY, Hirasawa T, Muramatsu T, Murakami M, Saito K, Mikami M. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1 α /GLUT-1 expression. Arch Gynecol Obstet 2008;277:539-46.
6. Miyazawa M, Yasuda M, Fujita M, Hirasawa T, Kajiwar H, Hirabayashi K, Ogane N, Shimizu M, Asanuma H, Murakami M, Takekoshi S, Mikami M, Osamura RY. Association of hypoxia-inducible factor-1 (HIF-1) expression with histology in epithelial ovarian tumors: A quantitative analysis of HIF-1. Arch Gynecol Obstet 2009;279:789-96.
7. Miyazawa M, Yasuda M, Fujita M, Kajiwar H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY. Therapeutic strategy targeting at mTOR-HIF-1 α -VEGF pathway for ovarian clear cell adenocarcinoma. Pathol Int 2009;59:19-27.
8. Hirabayashi K, Yasuda M, Kajiwar H, Nakamura N, Sato S, Nishijima Y, Mikami M, Osamura RY. Clear cell adenocarcinoma arising from adenomyosis: A case report. Int J Gynecol Pathol. 2009;28:262-6.
9. Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y. Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol 2007;43:563-9.
10. Fujita M, Yasuda M, Kitatani K, Miyazawa M, Hirabayashi K, Takekoshi S, Iida T, Hirasawa T, Murakami M, Mikami M, Ishiwata I, Shimizu M, Osamura RY. An up-to-date anti-cancer treatment strategy focusing on HIF-1 α suppression: its application for refractory ovarian cancer. Acta Histochem Cytochem 2007;40:139-42.
11. Yasuda M, Shimizu M, Fujita M, Miyazawa M, Tang X, Kajiwar H, Osamura RY, Shoji S, Tokunaga M, Terachi T. Usefulness of hypoxia inducible factor-1 α in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy. Cancer Detect Prev 2007;31:396-401.

学会発表

1. Masanori Yasuda, Shinichi Hori, Masaki Miyazawa, Hiroshi Kajiwar, Naoki Ogane, Michio Shimizu. Activated status of mTOR-HIF-1 α -VEGF pathway in ovarian clear cell adenocarcinoma. 98th Annual

- meeting of United States and Canadian Academy of Pathology, March 7-13, 2009, Boston.
2. 安田政実, 藤田麻里子, 宮澤昌樹, 平林健一, 梶原博, 平澤猛, 村松俊成, 村上優, 三上幹男. 卵巣明細胞腺癌・漿液性腺癌におけるHIF-1 α 活性化経路の探索. 第44回日本婦人科腫瘍学会学術集会. 平成20年7月17～19日. 名古屋.
 3. 宮澤昌樹, 藤田麻里子, 梶原博, 平林健一, 平澤猛, 西島義博, 村松俊成, 村上優, 浅沼秀樹, 大金直樹, 槻木恵一, 木口一成, 安田政実, 長村義之. 卵巣明細胞腺癌におけるmTOR-HIF-1 α 経路抑制による抗腫瘍効果の検討. 第97回日本病理学会総会. 平成20年5月15～17日. 金沢.